Bristol-Myers Squibb Stock News

Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET Company Participants Chris Boerner - Chief Executive Officer & Chairman Conference Call Participants Courtney Breen - Bernstein Courtney Breen Fantastic. Hi, everyone.

Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appears safe as well, as observed in the management's recent payout hike and the still rich cash flows despite the ongoing patent cliff impact. This is on top of the raised FY2025 guidance, given the accel...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications.

Bristol-Myers Squibb Company appears deeply undervalued, despite business headwinds and revenue declines from legacy products facing generic competition. The market is already pricing in revenue and EPS declines, but current valuation multiples—like a forward P/E below 7x—are excessively discounted. Even with conservative assumptions of 5% annual revenue decline and no terminal growth, fair val...

I reiterate my buy rating on Bristol-Myers, seeing significant undervaluation despite persistent weak technicals and sector underperformance. BMY's strong earnings beats, high free cash flow yield, and nearly 6% dividend make it a compelling income play, even amid pipeline concerns. Valuation is attractive: a sub-7x forward P/E and high dividend yield more than discount muted growth and generic...

Despite socio-economic challenges and pressure from the generic versions of Revlimid and Abraxane, Bristol-Myers Squibb Company's financial position continues to improve. It raised its 2025 diluted EPS guidance from $6.55-$6.85 to $6.7-$7, as well as revenue expectations from $45.5 billion to $45.8-$46.8 billion. Bristol-Myers Squibb's key franchises remain oncology and cardiovascular, primaril...

Focus on high-quality, dividend-paying stocks with temporary setbacks, offering both value and income for patient investors. Bristol-Myers Squibb is deeply undervalued, carries a 5.3% yield, strong profitability, and a promising neurodegenerative drug pipeline. Rexford Industrial Realty offers a 5% yield, benefits from supply-constrained Southern California industrial markets, and trades far be...